Nevro Corp (NVRO)

Currency in USD
5.84
0.00(0.00%)
Closed·
Showing Nevro Corp historical data. For real-time data please try another search
Day's Range
5.845.86
52 wk Range
3.1613.30
Key Statistics
Prev. Close
5.84
Open
5.84
Day's Range
5.84-5.86
52 wk Range
3.16-13.3
Volume
-
Average Volume (3m)
1.3M
1-Year Change
-31.62%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Nevro Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Nevro Corp Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, and offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, and HFX App, a patient remote control and the wireless trialing system. The company also provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, and surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was formerly known as NBI Development, Inc. and changed its name to Nevro Corp. in June 2007. The company was incorporated in 2006 and is based in Redwood City, California. As of April 3, 2025, Nevro Corp. operates as a subsidiary of Globus Medical, Inc.

Nevro Corp SWOT Analysis


Market Headwinds
Nevro faces declining sales and market share in the spinal cord stimulation sector, with challenges expected to persist through 2025
Strategic Pivot
Explore Nevro's product launches and acquisitions, including HFX AdaptivAI and Vyrsa SI joint therapy, aimed at diversifying revenue streams
Financial Outlook
Analysts project 2025 sales of $425 million, with price targets ranging from $4 to $7, reflecting cautious sentiment amid market uncertainties
Value Proposition
Delve into Nevro's strategic review process and strong cash position, which could unlock shareholder value despite current market challenges
Read full SWOT analysis

Nevro Corp Earnings Call Summary for Q3/2024

  • Q3 worldwide revenue down 6.7% to $96.9M; U.S. revenue fell 6.5% to $83.9M; U.S. SCS trials dropped 15.2%
  • Net loss from operations improved to $13.9M; adjusted EBITDA loss reduced to $1.8M; cash and equivalents up to $277M
  • HFX iQ with AdaptivAI technology released in limited market; full U.S. launch late Nov 2024, Europe Q1 2025
  • 2024 revenue guidance $400-405M (5-6% YoY decrease); adjusted EBITDA guidance raised to -$18M to -$16M
  • Focus on PDN market expansion, SI joint fusion growth, and leveraging AI for operational efficiency
Last Updated: 12/11/2024, 11:52
Read Full Transcript

Earnings

Latest Release
Jul 30, 2025
EPS / Forecast
-- / -0.5718
Revenue / Forecast
-- / 102.67M
EPS Revisions
Last 90 days

NVRO Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.